ZNTL azenosertib advances in platinum-resistant ovarian cancer
Azenosertib’s key clinical trials in platinum-resistant ovarian cancer are progressing, supported by robust safety oversight and a validated biomarker strategy.
Key clinical trials for azenosertib in platinum-resistant ovarian cancer are progressing, with robust safety oversight and a validated biomarker strategy. The drug is positioned as a differentiated, non-chemo oral option, with global regulatory alignment and a strong financial runway supporting ong…